homefeedbacksupportlog on 22-Nov-2008 
  Search
 
   
 
  Browse
ALL OF BIOLOGY

Pharmacology & Drug Discovery
Antimicrobial Agents
Cancer Therapeutics
Cardiovascular Pharmacology
Drug Discovery & Design
Endocrine & Metabolic Pharmacology
Gastrointestinal Pharmacology
Genito-Urinary & Reproductive Pharmacology
Immunopharmacology & Hematologic Pharmacology
Molecular Pharmacology
Musculoskeletal & Dermatologic Pharmacology
Neuropharmacology & Psychopharmacology
Pharmacogenomics
Pharmacokinetics & Drug Delivery
Renal Pharmacology
Respiratory Pharmacology
Toxicology
Related Sections
Bioinformatics
Biomacromolecule-Ligand Interactions
Cell Signalling
Cell Signalling & Trafficking Structures
Chemical Biology of the Cell
Directed Molecular Evolution
Genomics
Macromolecular Chemistry
Medical Genetics
Physiogenomics
Protein Chemistry & Proteomics
Small Molecule Chemistry

profile subject selected for My F1000 Biology

Browse > Pharmacology & Drug Discovery > Musculoskeletal & Dermatologic Pharmacology
Top 10 / All time Top 10 / Most viewed / Hidden jewels		Page 1 of 5. Select Page: 1 2 3 4 5 >>
Display 10 / 20 / 50 papers per page

printer friendly 
to email [Help]

Recommended
F1000 Factor 3.0

New Finding
 Reduction in hemoglobin-oxygen affinity results in the improvement of exercise capacity in mice with chronic heart failure.
Watanabe T, Takeda T, …, Shirasawa T, Otsu K
J Am Coll Cardiol 2008 Aug 26 52(9):779-86 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Michael Frenneaux with Julian O M Ormerod
Evaluated 12 Nov 2008

Recommended
F1000 Factor 3.0

New Finding
 TGF-beta-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis.
Wang H, Peters T, …, Weiss JM, Scharffetter-Kochanek K
J Clin Invest 2008 Jul 118(7):2629-39 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Mohamed Sayegh with Jessamyn Bagley
Evaluated 21 Oct 2008

Recommended
F1000 Factor 3.0

New Finding
Novel Drug Target
 The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis.
Bull MJ, Williams AS, …, Al-Shamkhani A, Wang EC
J Exp Med 2008 Sep 29 [abstract on PubMed] [related articles] [full text]
Selected by | Richard L. Stevens
Evaluated 10 Oct 2008

Recommended
F1000 Factor 3.0

New Finding
Novel Drug Target
 Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages.
Ha SD, Martins A, …, Chan BM, Kim SO
J Immunol 2008 Jul 1 181(1):690-7 [abstract on PubMed] [related articles] [order article]
Selected by | Robert Booth
Evaluated 25 Sep 2008

Recommended
F1000 Factor 3.0

Hypothesis
Novel Drug Target
 Collagen Fibril Formation: A NEW TARGET TO LIMIT FIBROSIS.
Chung HJ, Steplewski A, …, Uitto J, Fertala A
J Biol Chem 2008 Sep 19 283(38):25879-25886 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jonathan Jones
Evaluated 22 Sep 2008

Recommended
F1000 Factor 3.0

New Finding
Novel Drug Target
 Antigen-specific apheresis of human anti-acetylcholine receptor autoantibodies from myasthenia gravis patients' sera using Escherichia coli-expressed receptor domains.
Zisimopoulou P, Lagoumintzis G, Poulas K, Tzartos SJ
J Neuroimmunol 2008 Aug 30 200(1-2):133-41 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Lin Chen
Evaluated 17 Sep 2008

Must Read
F1000 Factor 6.0

New Finding
Novel Drug Target
 Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro.
Wang H, Yoshiko Y, …, Aubin JE, Maeda N
J Bone Miner Res 2008 Jun 23(6):939-48 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Eleanor Lederer
Evaluated 3 Sep 2008

Recommended
F1000 Factor 3.0

New Finding
 Cooperative synergy between NFAT and MyoD regulates myogenin expression and myogenesis.
Armand AS, Bourajjaj M, …, Redondo JM, De Windt LJ
J Biol Chem 2008 Aug 1 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Lin Chen
Evaluated 2 Sep 2008

Recommended
F1000 Factor 3.0

Hypothesis
New Finding
Novel Drug Target
 The initiation factor eIF3-f is a major target for atrogin1/MAFbx function in skeletal muscle atrophy.
Lagirand-Cantaloube J, Offner N, …, Segura CT, Leibovitch SA
EMBO J 2008 Apr 23 27(8):1266-76 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Paul Greenhaff with Andrew Murton
Evaluated 2 Sep 2008

Recommended
F1000 Factor 3.0

Confirmation
New Finding
 Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, 2000-2005.
Islam S, Liu Q, Chines A, Helzner E
Menopause 2008 Jul 25 [abstract on PubMed] [related articles] [full text]
Selected by | Henry Burger
Evaluated 21 Aug 2008


top of pagePage 1 of 5. Select Page: 1 2 3 4 5 >>
Display 10 / 20 / 50 papers per page

© 1999-2008 Biology Reports Ltd unless otherwise stated. < info@f1000.com >   Terms and conditions   Legal info